Analysis of the Infiltrative Features of Chordoma: The Relationship Between Micro-Skip Metastasis and Postoperative Outcomes

被引:18
作者
Akiyama, Toru [1 ]
Ogura, Koichi [2 ,3 ]
Gokita, Tabu [4 ]
Tsukushi, Satoshi [5 ]
Iwata, Shintaro [6 ]
Nakamura, Tomoki [7 ]
Matsumine, Akihiko [7 ]
Yonemoto, Tsukasa [6 ]
Nishida, Yoshihiro [8 ,9 ]
Saita, Kazuo [1 ]
Kawai, Akira [2 ]
Matsumoto, Seiichi [4 ]
Yamaguchi, Takehiko [10 ]
机构
[1] Jichi Med Univ, Saitama Med Ctr, Dept Orthopaed Surg, Saitama, Japan
[2] Natl Canc Ctr, Dept Musculoskeletal Oncol, Tokyo, Japan
[3] Univ Tokyo Hosp, Dept Orthopaed Surg, Tokyo, Japan
[4] Canc Inst Hosp, Dept Orthoped Surg, Tokyo, Japan
[5] Aichi Canc Ctr Hosp, Dept Orthoped Surg, Nagoya, Aichi, Japan
[6] Chiba Canc Ctr, Div Orthopaed Surg, Chiba, Japan
[7] Mie Univ Hosp, Dept Orthopaed Surg, Tsu, Mie, Japan
[8] Nagoya Univ, Dept Orthopaed Surg, Grad Sch, Nagoya, Aichi, Japan
[9] Sch Med, Nagoya, Aichi, Japan
[10] Dokkyo Med Univ, Saitama Med Ctr, Dept Pathol, Koshigaya, Japan
关键词
SOFT-TISSUE SARCOMA; VASCULAR INVASION; SACRAL CHORDOMAS; SURGICAL-MANAGEMENT; PROGNOSTIC-FACTORS; SACROCOCCYGEAL CHORDOMA; SACRECTOMY; RECURRENCE; CANCER; TUMORS;
D O I
10.1245/s10434-017-6268-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chordomas are very rare primary malignant bone tumors that arise commonly from the sacrum (50-60%) and clivus (25-35%). Chordomas have a high rate of recurrence. The authors confirmed a unique histologic infiltration pattern of chordomas that resembles a skip-metastatic lesion in normal tissue around tumor, which they named "micro-skip metastasis." This study aimed to examine the correlations between the clinicopathologic features of chordomas, including micro-skip metastasis, and the clinical outcomes, including overall survival, local recurrence-free survival, and distant metastasis-free survival. The study analyzed histopathologic and clinical data from patients with sacral chordomas who underwent en bloc resection from July 1991 through July 2014. Cases with a minimum follow-up period shorter than 20 months after resection were excluded. Kaplan-Meier survival analyses with log-rank tests were performed for overall survival, metastasis-free survival, and recurrence-free survival. The study retrospectively reviewed 40 patients. The mean follow-up period was 98.2 months (range 22-297 months). The local recurrence rate was 41.3%. Micro-skip metastases, observed in 17 patients (42.5%), were associated with a significantly increased risk of local recurrence (p = 0.023) but not with overall survival or distant metastasis-free survival. Poorer overall survival was associated with histologic vascular invasion (p = 0.030) and a greater maximum tumor diameter (p = 0.050). The presence of micro-skip metastasis was associated with a higher rate of local recurrence. The maximum tumor diameter and the presence of histologic vascular invasion were associated with poorer overall survival.
引用
收藏
页码:912 / 919
页数:8
相关论文
共 27 条
  • [21] Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas
    Stojadinovic, A
    Leung, DHY
    Hoos, A
    Jaques, DP
    Lewis, JJ
    Brennan, MF
    [J]. ANNALS OF SURGERY, 2002, 235 (03) : 424 - 434
  • [22] Chordoma: current concepts, management, and future directions
    Walcott, Brian P.
    Nahed, Brian V.
    Mohyeldin, Ahmed
    Coumans, Jean-Valery
    Kahle, Kristopher T.
    Ferreira, Manuel J.
    [J]. LANCET ONCOLOGY, 2012, 13 (02) : E69 - E76
  • [23] Histological vascular invasion is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
    Wang, Hua
    Li, Pengfei
    Zhang, Xinke
    Xia, Zhongjun
    Lu, Yue
    Huang, Huiqiang
    [J]. ONCOLOGY LETTERS, 2016, 12 (02) : 825 - 836
  • [24] Distinguishing benign notochordal cell tumors from vertebral chordoma
    Yamaguchi, Takehiko
    Iwata, Jun
    Sugihara, Shinsuke
    McCarthy, Edward F., Jr.
    Karita, Michiaki
    Murakami, Hideki
    Kawahara, Norio
    Tsuchiya, Hiroyuki
    Tomita, Katsuro
    [J]. SKELETAL RADIOLOGY, 2008, 37 (04) : 291 - 299
  • [25] Yonemoto T, 2005, ANTICANCER RES, V25, P1337
  • [26] Yonemoto T, 1999, CANCER, V85, P878, DOI 10.1002/(SICI)1097-0142(19990215)85:4<878::AID-CNCR15>3.3.CO
  • [27] 2-Z